CLINICAL TRIAL

STAR-C Virtual Training and Follow-up (STAR-VTF) for Alzheimer Disease

Recruiting · 18+ · All Sexes · Seattle, WA

Cultural Adaptation of a Behavioral Intervention for Latino Caregivers

See full description

About the trial for Alzheimer Disease

Eligible Conditions
Dementia · Alzheimer Disease

Treatment Groups

This trial involves 2 different treatments. STAR-C Virtual Training And Follow-up (STAR-VTF) is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
STAR-C Virtual Training and Follow-up (STAR-VTF)
BEHAVIORAL
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex aged 18 and older. There are 4 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
People who are 18 years or older are legally allowed to drink alcohol. show original
If you are a family member or close friend of someone with ADRD, you may be looking for information on how to best support them show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 2 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 2 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether STAR-C Virtual Training and Follow-up (STAR-VTF) will improve 2 primary outcomes in patients with Alzheimer Disease. Measurement will happen over the course of 2 months.

Potential Effectiveness
2 MONTHS
To assess potential effectiveness, the investigators will measure (2) caregiver depression. For caregiver depression, the investigators will use the full Patient Health Questionnaire (PHQ)-9. PHQ-9 is the major depressive disorder (MDD) module of the full PHQ. Used to provisionally diagnose depression and grade severity of symptoms in general medical and mental health settings. Scores each of the 9 Diagnostic and Statistical Manual Diploma in Social Medicine (DSM) criteria of MDD as "0" (not at all) to "3" (nearly every day), providing a 0-27 severity score. Higher PHQ-9 scores are associated with decreased functional status and increased symptom-related difficulties, sick days, and healthcare utilization.
Acceptability
2 MONTHS
To assess acceptability, the investigators will measure (3) perceived usefulness. For perceived usefulness, the investigators will administer the Perceived Usefulness Scale. It consists of a 6 item questionnaire, all items are measured on a 7-point Likert-type scale ranging from "strongly disagree" (score 1) to "strongly agree" (score 7).

Who is running the study

Principal Investigator
M. R.
Prof. Magaly Ramirez, Assistant Professor, School of Public Health
University of Washington

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people get alzheimer disease a year in the United States?

Of the 33,745 individuals with a diagnosis of dementia in the sample, 8,897 (25.4%) had Alzheimer disease, and 21,972 (74.7%) had other types of dementia. The annual incidence of Alzheimer disease in the United States is 5.9 per 100,000 inhabitants per year.

Anonymous Patient Answer

Can alzheimer disease be cured?

There is no cure for Alzheimer's disease, because no therapy is effective for the disease itself but is available to delay the progressive damage of the disease. At present, research interventions include treatments for people who have Alzheimer's Disease, and research into new medicines are ongoing. Patients can help by encouraging their family members to become involved in Alzheimer's disease research; if they know that there is no cure for the disease, they are more likely to be supportive, as well as providing care for family members who have or are at risk of developing the condition.

Anonymous Patient Answer

What are common treatments for alzheimer disease?

Results from a recent clinical trial presents the majority of existing therapies for Alzheimers disease. This article mainly emphasizes the use of currently available medications and treatments for the disease. This article did not include many innovative techniques that show a promising result for further development by the scientific community, such as anti-amyloid approaches.

Anonymous Patient Answer

What is alzheimer disease?

This section summarizes how Alzheimer's Disease (AD) is characterized. AD is a disease that begins slowly and worsens with no specific risk factors. The typical symptoms include behavioral changes such as decreased social skills, problems with memory and thinking, and other signs of mind change like inability to talk or walk or changes in hearing and vision. By the time symptoms are recognized AD usually has progressed to a late stage, when the brain's ability to support the mind is exhausted.\n

Anonymous Patient Answer

What causes alzheimer disease?

It is not completely clear why so many elderly people develop AD. However, it is known that genetic, environmental, and lifestyle factors play a role the development of AD. Aspects of diet that are associated with the risk and severity of AD are obesity, the consumption of alcoholic beverages and the use of non-steroidal anti-inflammatory drugs. Other environmental factors found to be associated with the development of AD include pollutants such as dioxin that are derived from industrial emissions.\n

Anonymous Patient Answer

What are the signs of alzheimer disease?

For many people, the first symptom of probable AD is difficulty with recalling names or personal information; this may be the only sign they see that suggests that they may have early AD. Most adults will develop a significant degree of cognitive decline, but by the time they receive a diagnosis the problem has mostly resolved; the term prodromal AD applies to milder levels of cognitive impairment such as episodic memory and executive function difficulties earlier in the disease progression. There may still be difficulty with some cognitive functions such as visual memory, though, and some patients with AD may have no cognitive or physical signs at all. There may be other signs such as changes in personality.

Anonymous Patient Answer

What is the latest research for alzheimer disease?

Current research findings are hopeful for the treatment of Alzheimer's disease. One type of treatments involves [neuroprotection agents]. Neuroprotective agents are [protein precursors that] try to protect biological neurons from damage by the accumulation of [amyloid] plaques and tangles. These pre-clinical discoveries suggest that future treatments may show some success in treating Alzheimer's disease. There are currently no medications approved for the treatment of Alzheimer's disease. However, many [neuroprotectants] are in clinical trials [in 2016, 2017], so future research and treatment may show some success. [Power](http://www.withpower.

Anonymous Patient Answer

How serious can alzheimer disease be?

The prevalence of AD in Italy is higher than anywhere else in the world. The disease has major impact on patients' well-being: they usually have dementia. Alzheimer disease is the most frequent cause of dementia; it is responsible for a quarter of all dementia cases (5-20% of all cases in the general population). Moreover, almost all patients also have Alzheimer-related problems like aggression, agitation and behavioural problems. There are also a small number of patients affected by other forms of dementia like vascular dementia, frontotemporal dementia and Lewy body dementia. Therefore, the prevalence of AD is underestimated in Italy.

Anonymous Patient Answer

What are the common side effects of star-c virtual training and follow-up (star-vtf)?

Findings from a recent study shows that star-vtf can be a feasible and practical approach to virtual training of seniors. Because of such, star-vtf should be developed further.

Anonymous Patient Answer

How does star-c virtual training and follow-up (star-vtf) work?

Starvtf can reduce dementia symptomatology after only one session. Starvtf can be used at home as a form of patient education and support, with the help of a qualified caregiver. This is an inexpensive and simple method for helping caregivers get the care they require.

Anonymous Patient Answer

What are the latest developments in star-c virtual training and follow-up (star-vtf) for therapeutic use?

Star-vtf provides personalized VFT that can improve cognition, behavior and emotion and may reduce depressive symptoms. A further reduction in cost and time saved compared with traditional VFT will encourage improved use of this inexpensive, free, therapeutic VFT modality.

Anonymous Patient Answer

What is the primary cause of alzheimer disease?

While the most common form of this disease is undoubtedly Alzheimer disease, the disease may also be associated with some other, less-common types of dementia and other diseases, or is accompanied by symptoms of psychosis, hallucinations, delusions, and abnormal behavior. The most recent revision of the nosology is not a revision of the primary pathology; it may be a revision of the symptoms and symptoms that can be seen in some of the disorders that can be called Alzheimer's disease. Clinically defined Alzheimer's disease and other forms of senile dementia may be grouped together and have some common pathologic factors, but it is certainly a misnomer to suggest that this is a revision of a primary pathology.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Alzheimer Disease by sharing your contact details with the study coordinator.